Developer docs
API playgroundTry for free, no card

Search company profiles

Valgen Medtech

Full company profile

uuid0002kz9

Namestring
Valgen Medtech
Legal namestring
杭州德晋医疗科技有限公司
Websiteurl
valgenmed.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Valgen Medtech (杭州德晋医疗科技有限公司) is a Hangzhou, China-based medical device company founded in 2015 that develops interventional products for structural heart disease, with primary focus on transcatheter edge-to-edge repair (TEER) systems for mitral and tricuspid regurgitation. The company's flagship product is the DragonFly transcatheter mitral valve clip system, supported by a portfolio of complementary devices and accessories including the MitralStitch transapical mitral repair system, the DragonFly-T transcatheter tricuspid repair system, the DragonFire transcatheter RF ablation system for HOCM, and procedure-enabling accessories such as the Magpie balloon dilation catheter, DragonPath transseptal puncture system, Firework stiff guidewire, Pu Jie Jie X-ray protective screen, and an Adjustable Curved Introducer Sheath. Valgen serves cardiac surgery centers and interventional cardiology hospitals, with DragonFly implants performed in approximately 300 hospitals in China and the company holding regulatory approvals in 15+ countries.

The business model is B2B sale of high-value, single-use interventional devices on a per-procedure basis, with revenue generated by hospital procurement of the clip system and required accessories. Commercial reach is reinforced by the Long Fei Academy physician training program, which conducts more than 100 training events per year and serves as both a clinical adoption engine and a switching-cost moat. In 2025 Valgen performed 2,043 DragonFly implants in China and captured 47.14% of the China TEER market, the leading domestic position. Clinical evidence supporting commercial traction includes 87.5% one-year and 82.5% three-year DMR composite success rates in China, 86.7% one-year DMR and 97.4% procedural success in the EU, and 96.2% device success for DragonFly-T. The company is a privately-held subsidiary of Deno Healthcare Group, backed by DCP and Sequoia China following a $188M Series B in 2021, and was recognized as a Unicorn Enterprise.

Recent strategic priorities include expanding the DragonFly indication scope (DMR and FMR approvals in the EU), launching the DragonFire HOCM ablation line, developing the next-generation DragonFly M2 platform, and executing a sequenced international rollout into the EU, Latin America, the Middle East, and Southeast Asia. The company has 250+ employees, 600+ patents filed with 200+ granted, overseas R&D and clinical training centers, and a leadership team led by CEO Yiwei Zhao and General Manager Dr. Zhang Tingchao. A 2026 headquarters relocation is planned to support continued scale-up.

Short descriptiontext

Valgen Medtech is a Chinese medical device company developing transcatheter edge-to-edge repair (TEER) systems for mitral and tricuspid valve disease. Its flagship DragonFly holds #1 China TEER market share, with 2,000+ procedures performed across 15+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHangzhou, China
HQ citystring
Hangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter mitral repair, structural heart devices, interventional cardiology devices, cardiac valve implants, edge-to-edge repair systems
Industry1 code
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Interventional Cardiology Devices — Structural Heart (Transcatheter Mitral and Tricuspid Valve Repair)
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical device sales (capital equipment & consumables)
TypeHardware Sales
Description

Primary revenue from one-time/transaction-based sales of Class III medical devices (DragonFly™ mitral clip system, Magpie™ balloon dilation catheter, DragonPath™ transseptal puncture system, Pu Jie Jie™ X-ray shield, Stiff guidewires) to hospitals and clinical centers; 2,000+ DragonFly™ surgeries across ~300 hospitals in China by end of 2025.

valgenmed.com
2International device sales & overseas commercialization
TypeHardware Sales
Description

Revenue from DragonFly™ and other device sales in approved international markets including Hong Kong, Indonesia, Colombia, Turkey, Peru, Brazil, Saudi Arabia, Jordan, Panama, Philippines, Vietnam, Argentina, and EU; commercial adoption underway in Latin America and Southeast Asia.

valgenmed.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1DragonFly™
Description

Transcatheter mitral valve clip system (and the DragonFly-T variant for tricuspid repair); the company's flagship product line, including next-generation DragonFly M2 steerable introducer sheath.

valgenmed.com
+6 more records
Core offering1 text field

Valgen Medtech develops, manufactures, and commercializes Class III transcatheter interventional medical devices for structural heart disease, primarily mitral and tricuspid valve regurgitation. Its flagship DragonFly™ transcatheter mitral valve clip system performs transfemoral-transseptal edge-to-edge repair (TEER) and is sold alongside a procedural toolkit of supporting devices (MitralStitch®, DragonFly-T®, DragonFire®, DragonPath™, Magpie™, Pu Jie Jie™, stiff guidewires, and an adjustable curved introducer sheath) used by interventional cardiologists in hospitals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 87.5% 1-year composite treatment success in DragonFly-DMR Chinese pivotal trial (n=120)
+8 more records
Product overview1 text field

Valgen Medtech operates as a single unified structural heart disease interventional medical device company with a platform-plus-modules product architecture centered on the DragonFly™ product family for transcatheter mitral and tricuspid valve repair. The core product DragonFly™ Transcatheter Mitral Valve Clip System (transfemoral venous approach) is supported by a comprehensive procedural toolkit including the MitralStitch® (transapical mitral valve repair), DragonFly-T® (transcatheter tricuspid valve repair, in clinical research), and DragonFire® (transcatheter radiofrequency ablation for hypertrophic cardiomyopathy, in innovation channel). The system is complemented by accessory/supporting products that together form a complete procedural solution: DragonPath™ (atrial septal puncture system), Magpie™ (balloon dilation catheter), Firework™ stiff guidewire series, Pu Jie Jie™ (medical X-ray protective screen), and the newly approved Adjustable Curved Introducer Sheath. This integrated portfolio enables both mitral and tricuspid valve transcatheter edge-to-edge repair (TEER) procedures through transfemoral venous and transapical approaches, with the DragonFly™ serving as the flagship product that achieved #1 market share in China's TEER market in 2025 with 47.14% of total Chinese TEER implant volume.

Product and service9 records
1DragonFly™ Transcatheter Mitral Valve Clip System
CategoryCore Product — Transcatheter Mitral Valve Repair (TEER)
Description

Transfemoral venous transcatheter mitral valve edge-to-edge repair (TEER) system for treating degenerative mitral regurgitation (DMR) and functional mitral regurgitation (FMR) in high-surgical-risk adult patients. Features 4 clip specifications, 45° adjustable closure angle, independent leaflet capture, central occluder mesh, and visualized quantitative operating system. Sold to interventional cardiologists at tertiary hospitals and cardiac centers.

2DragonFly-T® Transcatheter Tricuspid Valve Edge-to-Edge Repair System
CategoryCore Product — Transcatheter Tricuspid Valve Repair (T-TEER)
Description

Transcatheter tricuspid valve edge-to-edge repair (T-TEER) system designed specifically for tricuspid valve anatomy. FIM feasibility study showed 96.2% device success rate and 89.8% of patients achieving ≥1-grade TR reduction at 12 months. Sold / studied at tertiary cardiology centers performing tricuspid interventions.

3MitralStitch® Transapical Mitral Valve Repair System
CategoryTransapical Mitral Valve Repair Device
Description

Transapical beating-heart mitral valve repair system capable of both artificial chordae implantation and edge-to-edge repair. Uses unique atrial-side pad and U-shaped suture design that reduces leaflet tension and preserves physiologic repair. Sold to interventional cardiology centers performing transapical mitral repair.

4DragonFire® Transcatheter Myocardial Radiofrequency Ablation System
CategoryPipeline Product — HOCM RF Ablation
Description

Transcatheter myocardial radiofrequency ablation system for treating hypertrophic obstructive cardiomyopathy (HOCM) patients. Minimally invasive, precise, and safe approach addressing a previously underserved Chinese HOCM treatment market. Targeted at interventional cardiologists and HCM programs.

5Magpie™ Balloon Dilation Catheter
CategorySupporting Product — Balloon Dilation Catheter
Description

Non-compliant balloon dilation catheter suitable for dilation of the native aortic valve of the heart (not for post-dilation after prosthetic valve implantation). Features high rated burst pressure, rapid inflation/deflation, eight-petal folding wing design, and reinforced inner tube. Supporting product for Valgen's structural heart procedures.

6DragonPath™ Atrial Septal Puncture System
CategorySupporting Product — Transseptal Access System
Description

Transseptal puncture system with optimized puncture sheath hardness, kink resistance, and torque performance; needle designed for stronger puncture force with appropriate tip angle. Used to establish transfemoral-transseptal access for the DragonFly™ TEER procedure.

7Pu Jie Jie™ Medical X-ray Protective Screen
CategorySupporting Product — Radiation Protection
Description

Medical X-ray radiation protective screen used for radiation protection during diagnostic radiology procedures. Features include a unique operation window, ultrasound probe hook, arm support bracket, suspension bracket, and cable management box. Supporting consumable product for interventional procedures.

8Firework™ Stiff Guidewire Series
CategorySupporting Product — Cardiovascular Guidewire
Description

Stiff guidewire series for cardiovascular (non-coronary) interventional diagnosis and treatment procedures, used to guide device insertion and positioning or to establish vascular access.

9Adjustable Curved Introducer Sheath (可调弯导引鞘)
CategorySupporting Product — Transseptal Introducer Sheath
Description

NMPA-approved adjustable curved introducer sheath that overcomes large-sheath mid-sheath locking limitations, enabling improved Aorta Hugger performance in challenging transseptal cases. Supporting accessory for the DragonFly™ TEER procedure.

Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-07-01
Description

Co-developed DragonFly™ with Prof. Wang Jian'an's team at the Second Affiliated Hospital of Zhejiang University (now Academician Wang Jian'an's team). The first clinical use of DragonFly™ was performed by this team on July 23, 2020. They are the principal investigators for the DragonFly-DMR China pivotal trial, DragonFly-DMR EU Pivotal Study (at University Hospital Bonn), and DragonFly-T® FIM study. They broadcasted the first T-TEER case using DragonFly™ at CSI Frankfurt 2026.

2Sichuan University National Biomaterials Engineering Research Center - Prof. Zhang Xingdong team (四川大学国家生物材料工程研究中心)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-07-01
Description

Co-developed DragonFly™ with Prof. Zhang Xingdong (Academician) and his team at the Sichuan University National Biomaterials Engineering Research Center. Co-led nearly a decade of R&D and jointly commercialized the device globally.

valgenmed.com
3Denuo Medical Group (德诺医疗集团 / 德诺医疗)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Valgen Medtech is a subsidiary / portfolio company of Denuo Medical Group, with Mr. Zi Zhenjun (訾振军) as Denuo's founding investor. Valgen operates the DragonFly™, MitralStitch®, DragonFire®, and other structural heart product lines under Denuo's umbrella; participates in Denuo's broader "Belt and Road" structural heart disease medical cooperation program with the National Center for Cardiovascular Disease.

valgenmed.com
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive strategic marketing cooperation agreement with Qiming Medical (Venus Medtech) to accelerate promotion of cardiac valve disease diagnosis and treatment technology in China. Drives the bulk of Valgen's domestic channel sales and clinical adoption.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Lead European clinical research partner for DragonFly-EU Pivotal Study (8 European centers, 39 patients). Prof. Nickenig serves as principal investigator, presenting 1-year EU data at CSI Frankfurt 2026 and DragonFly-FMR 12-month data at EuroPCR 2025. Bonn Heart Center is a key global KOL partner.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Key clinical partner for "Belt and Road" international medical cooperation; treated an El Salvador medical expert with DragonFly™ in November 2025; conducts physician training and case demonstrations. Signed cooperation agreement with Rosales National Hospital in El Salvador (April 2025) and is a key node in Valgen's international clinical strategy.

7ASV Yaşam Hospital, Antalya, Turkey - Prof. Ismail Ateş
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Turkish clinical partner presenting real-world evidence on 5 high-risk cases of complex mitral/tricuspid regurgitation at CSI Frankfurt 2026; serves as a key KOL reference for the Turkish and broader European market.

valgenmed.com
8Fuwai Hospital, Chinese Academy of Medical Sciences - Prof. Pan Xiangbin team (中国医学科学院阜外医院)
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Key clinical partner in the development and clinical research of MitralStitch® — performed the first China-original DMR interventional case in 2018 and led the first-in-human clinical applications; supports "Belt and Road" medical cooperation programs.

valgenmed.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Brazilian clinical center that performed the first Latin American commercial implant of DragonFly™ on April 30, 2026, validating device performance in complex AFMR cases.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Performed the first Vietnam commercial implant of DragonFly™ on April 22, 2026 — a key clinical site for the Belt and Road Southeast Asia market entry.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1MicroPort Scientific
TypeBroad incumbent
Description

Large Chinese medical device conglomerate with structural heart and other interventional portfolios. A broad incumbent with overlapping capabilities in structural heart and a wide distribution network across Chinese hospitals.

TypeDirect peer
Description

Chinese structural heart company with a mitral and tricuspid valve interventional device portfolio. A direct domestic competitor to Valgen in the Chinese TEER and broader structural heart space, also pursuing international regulatory approvals.

TypeEmerging player
Description

Italy-based developer of the Saturn transcatheter mitral valve replacement system. An emerging player in the mitral regurgitation interventional space, focused on TMVR rather than TEER, addressing a related but distinct patient segment.

TypeRegional player
Description

Chinese structural heart company developing transcatheter valve products. A regional peer competing in the Chinese structural heart interventional market with overlapping target indications.

TypeEmerging player
Description

Developer of the Carillon Mitral Contour System for functional mitral regurgitation. An emerging transcatheter alternative in the FMR space, addressing a subset of the same patient population that DragonFly™ is approved for (DragonFly received EU FMR approval in May 2026).

TypeBroad incumbent
Description

Developer of the PASCAL transcatheter valve repair system, the second major global TEER platform competing directly with DragonFly™ and MitraClip. Edwards is a broad structural heart incumbent with established reimbursement and KOL penetration in EU and US markets.

TypeEmerging player
Description

US-based company developing the AltaValve transcatheter mitral valve replacement system. A partial competitor in the mitral regurgitation treatment space; overlaps in target patient population (high-risk MR) but with a different mechanism (TMVR vs TEER).

8Venus Medtech (Qiming Medical)
TypeDirect peer
Description

Chinese structural heart company developing VenusP-Valve and other transcatheter valve products. Both a strategic investor in Valgen (participated in Series B) and exclusive domestic channel partner (Qiming Medical) for DragonFly™, as well as a peer in the broader Chinese structural heart interventional space.

TypeDirect peer
Description

Chinese medical device company developing the JensClip transcatheter mitral valve repair system, a direct domestic competitor to Valgen's DragonFly™ in the China TEER market. Competes for the same hospital accounts, surgeon training programs, and provincial reimbursement slots.

10Abbott
TypeBroad incumbent
Description

Global market leader in transcatheter mitral repair via the MitraClip system (now multi-generation G4). Directly competes with Valgen's DragonFly™ in both China and international markets, with the deepest global KOL network, longest follow-up data, and broadest reimbursement footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valgen Medtech

Interventional Cardiology Devices — Structural Heart (Transcatheter Mitral and Tricuspid Valve Repair)valgenmed.com

Valgen Medtech is a Chinese medical device company developing transcatheter edge-to-edge repair (TEER) systems for mitral and tricuspid valve disease. Its flagship DragonFly holds #1 China TEER market share, with 2,000+ procedures performed across 15+ countries.

What Valgen Medtech does

Valgen Medtech (杭州德晋医疗科技有限公司) is a Hangzhou, China-based medical device company founded in 2015 that develops interventional products for structural heart disease, with primary focus on transcatheter edge-to-edge repair (TEER) systems for mitral and tricuspid regurgitation. The company's flagship product is the DragonFly transcatheter mitral valve clip system, supported by a portfolio of complementary devices and accessories including the MitralStitch transapical mitral repair system, the DragonFly-T transcatheter tricuspid repair system, the DragonFire transcatheter RF ablation system for HOCM, and procedure-enabling accessories such as the Magpie balloon dilation catheter, DragonPath transseptal puncture system, Firework stiff guidewire, Pu Jie Jie X-ray protective screen, and an Adjustable Curved Introducer Sheath. Valgen serves cardiac surgery centers and interventional cardiology hospitals, with DragonFly implants performed in approximately 300 hospitals in China and the company holding regulatory approvals in 15+ countries.

The business model is B2B sale of high-value, single-use interventional devices on a per-procedure basis, with revenue generated by hospital procurement of the clip system and required accessories. Commercial reach is reinforced by the Long Fei Academy physician training program, which conducts more than 100 training events per year and serves as both a clinical adoption engine and a switching-cost moat. In 2025 Valgen performed 2,043 DragonFly implants in China and captured 47.14% of the China TEER market, the leading domestic position. Clinical evidence supporting commercial traction includes 87.5% one-year and 82.5% three-year DMR composite success rates in China, 86.7% one-year DMR and 97.4% procedural success in the EU, and 96.2% device success for DragonFly-T. The company is a privately-held subsidiary of Deno Healthcare Group, backed by DCP and Sequoia China following a $188M Series B in 2021, and was recognized as a Unicorn Enterprise.

Recent strategic priorities include expanding the DragonFly indication scope (DMR and FMR approvals in the EU), launching the DragonFire HOCM ablation line, developing the next-generation DragonFly M2 platform, and executing a sequenced international rollout into the EU, Latin America, the Middle East, and Southeast Asia. The company has 250+ employees, 600+ patents filed with 200+ granted, overseas R&D and clinical training centers, and a leadership team led by CEO Yiwei Zhao and General Manager Dr. Zhang Tingchao. A 2026 headquarters relocation is planned to support continued scale-up.

Valgen Medtech firmographics

Firmographics
Name
Valgen Medtech
Legal name
杭州德晋医疗科技有限公司
Website
https://valgenmed.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Valgen Medtech is a Chinese medical device company developing transcatheter edge-to-edge repair (TEER) systems for mitral and tricuspid valve disease. Its flagship DragonFly holds #1 China TEER market share, with 2,000+ procedures performed across 15+ countries.
Ownership category
akta.pro rank

Valgen Medtech industry classification

Industry
Product category
Interventional Cardiology Devices — Structural Heart (Transcatheter Mitral and Tricuspid Valve Repair)
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Transcatheter mitral repair
  • Structural heart devices
  • Interventional cardiology devices
  • Cardiac valve implants
  • Edge-to-edge repair systems

Where Valgen Medtech is headquartered

Location

Headquarters

HQ city
Hangzhou
HQ country
China
HQ region
Asia

Offices5 records

Markets served

Valgen Medtech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Others

Revenue model

  1. Medical device sales (capital equipment & consumables): Primary revenue from one-time/transaction-based sales of Class III medical devices (DragonFly™ mitral clip system, Magpie™ balloon dilation catheter, DragonPath™ transseptal puncture system, Pu Jie Jie™ X-ray shield, Stiff guidewires) to hospitals and clinical centers; 2,000+ DragonFly™ surgeries across ~300 hospitals in China by end of 2025.
  2. International device sales & overseas commercialization: Revenue from DragonFly™ and other device sales in approved international markets including Hong Kong, Indonesia, Colombia, Turkey, Peru, Brazil, Saudi Arabia, Jordan, Panama, Philippines, Vietnam, Argentina, and EU; commercial adoption underway in Latin America and Southeast Asia.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels9 records

Valgen Medtech product offering

Product offering

Core offering

Valgen Medtech develops, manufactures, and commercializes Class III transcatheter interventional medical devices for structural heart disease, primarily mitral and tricuspid valve regurgitation. Its flagship DragonFly™ transcatheter mitral valve clip system performs transfemoral-transseptal edge-to-edge repair (TEER) and is sold alongside a procedural toolkit of supporting devices (MitralStitch®, DragonFly-T®, DragonFire®, DragonPath™, Magpie™, Pu Jie Jie™, stiff guidewires, and an adjustable curved introducer sheath) used by interventional cardiologists in hospitals.

Product overview

Valgen Medtech operates as a single unified structural heart disease interventional medical device company with a platform-plus-modules product architecture centered on the DragonFly™ product family for transcatheter mitral and tricuspid valve repair. The core product DragonFly™ Transcatheter Mitral Valve Clip System (transfemoral venous approach) is supported by a comprehensive procedural toolkit including the MitralStitch® (transapical mitral valve repair), DragonFly-T® (transcatheter tricuspid valve repair, in clinical research), and DragonFire® (transcatheter radiofrequency ablation for hypertrophic cardiomyopathy, in innovation channel). The system is complemented by accessory/supporting products that together form a complete procedural solution: DragonPath™ (atrial septal puncture system), Magpie™ (balloon dilation catheter), Firework™ stiff guidewire series, Pu Jie Jie™ (medical X-ray protective screen), and the newly approved Adjustable Curved Introducer Sheath. This integrated portfolio enables both mitral and tricuspid valve transcatheter edge-to-edge repair (TEER) procedures through transfemoral venous and transapical approaches, with the DragonFly™ serving as the flagship product that achieved #1 market share in China's TEER market in 2025 with 47.14% of total Chinese TEER implant volume.

Differentiator

Problem solved

Functional benefit

Brands

  • DragonFly™: Transcatheter mitral valve clip system (and the DragonFly-T variant for tricuspid repair); the company's flagship product line, including next-generation DragonFly M2 steerable introducer sheath.
  • Pu Jie Jie™ (蒲姐姐)
  • Magpie™
  • DragonPath™
  • Firework™ (硬导丝 stiff guidewire series)
  • DragonFire®
  • MitralStitch®

Products and services

  • DragonFly™ Transcatheter Mitral Valve Clip System Transfemoral venous transcatheter mitral valve edge-to-edge repair (TEER) system for treating degenerative mitral regurgitation (DMR) and functional mitral regurgitation (FMR) in high-surgical-risk adult patients. Features 4 clip specifications, 45° adjustable closure angle, independent leaflet capture, central occluder mesh, and visualized quantitative operating system. Sold to interventional cardiologists at tertiary hospitals and cardiac centers.
  • DragonFly-T® Transcatheter Tricuspid Valve Edge-to-Edge Repair System Transcatheter tricuspid valve edge-to-edge repair (T-TEER) system designed specifically for tricuspid valve anatomy. FIM feasibility study showed 96.2% device success rate and 89.8% of patients achieving ≥1-grade TR reduction at 12 months. Sold / studied at tertiary cardiology centers performing tricuspid interventions.
  • MitralStitch® Transapical Mitral Valve Repair System Transapical beating-heart mitral valve repair system capable of both artificial chordae implantation and edge-to-edge repair. Uses unique atrial-side pad and U-shaped suture design that reduces leaflet tension and preserves physiologic repair. Sold to interventional cardiology centers performing transapical mitral repair.
  • DragonFire® Transcatheter Myocardial Radiofrequency Ablation System Transcatheter myocardial radiofrequency ablation system for treating hypertrophic obstructive cardiomyopathy (HOCM) patients. Minimally invasive, precise, and safe approach addressing a previously underserved Chinese HOCM treatment market. Targeted at interventional cardiologists and HCM programs.
  • Magpie™ Balloon Dilation Catheter Non-compliant balloon dilation catheter suitable for dilation of the native aortic valve of the heart (not for post-dilation after prosthetic valve implantation). Features high rated burst pressure, rapid inflation/deflation, eight-petal folding wing design, and reinforced inner tube. Supporting product for Valgen's structural heart procedures.
  • DragonPath™ Atrial Septal Puncture System Transseptal puncture system with optimized puncture sheath hardness, kink resistance, and torque performance; needle designed for stronger puncture force with appropriate tip angle. Used to establish transfemoral-transseptal access for the DragonFly™ TEER procedure.
  • Pu Jie Jie™ Medical X-ray Protective Screen Medical X-ray radiation protective screen used for radiation protection during diagnostic radiology procedures. Features include a unique operation window, ultrasound probe hook, arm support bracket, suspension bracket, and cable management box. Supporting consumable product for interventional procedures.
  • Firework™ Stiff Guidewire Series Stiff guidewire series for cardiovascular (non-coronary) interventional diagnosis and treatment procedures, used to guide device insertion and positioning or to establish vascular access.
  • Adjustable Curved Introducer Sheath (可调弯导引鞘) NMPA-approved adjustable curved introducer sheath that overcomes large-sheath mid-sheath locking limitations, enabling improved Aorta Hugger performance in challenging transseptal cases. Supporting accessory for the DragonFly™ TEER procedure.

Quantifiable outcome

  • 87.5% 1-year composite treatment success in DragonFly-DMR Chinese pivotal trial (n=120)
  • +8 more outcomes

Companies that use Valgen Medtech

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Valgen Medtech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

Valgen Medtech partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

  • Second Affiliated Hospital of Zhejiang University, School of Medicine (浙大二院) - Prof. Wang Jian'an teamflagshipStrategic or Co-development Partner · 1 July 2020Co-developed DragonFly™ with Prof. Wang Jian'an's team at the Second Affiliated Hospital of Zhejiang University (now Academician Wang Jian'an's team). The first clinical use of DragonFly™ was performed by this team on July 23, 2020. They are the principal investigators for the DragonFly-DMR China pivotal trial, DragonFly-DMR EU Pivotal Study (at University Hospital Bonn), and DragonFly-T® FIM study. They broadcasted the first T-TEER case using DragonFly™ at CSI Frankfurt 2026.
  • Sichuan University National Biomaterials Engineering Research Center - Prof. Zhang Xingdong team (四川大学国家生物材料工程研究中心)flagshipStrategic or Co-development Partner · 1 July 2020Co-developed DragonFly™ with Prof. Zhang Xingdong (Academician) and his team at the Sichuan University National Biomaterials Engineering Research Center. Co-led nearly a decade of R&D and jointly commercialized the device globally.
  • Denuo Medical Group (德诺医疗集团 / 德诺医疗)flagshipStrategic or Co-development Partner · 1 January 2018Valgen Medtech is a subsidiary / portfolio company of Denuo Medical Group, with Mr. Zi Zhenjun (訾振军) as Denuo's founding investor. Valgen operates the DragonFly™, MitralStitch®, DragonFire®, and other structural heart product lines under Denuo's umbrella; participates in Denuo's broader "Belt and Road" structural heart disease medical cooperation program with the National Center for Cardiovascular Disease.
  • Qiming Medical / Venus Medtech (启明医疗)flagshipChannel Partner/ Reseller/ DistributorExclusive strategic marketing cooperation agreement with Qiming Medical (Venus Medtech) to accelerate promotion of cardiac valve disease diagnosis and treatment technology in China. Drives the bulk of Valgen's domestic channel sales and clinical adoption.
  • University Hospital Bonn (Universitätsklinikums Bonn) - Prof. Georg NickenigflagshipStrategic or Co-development PartnerLead European clinical research partner for DragonFly-EU Pivotal Study (8 European centers, 39 patients). Prof. Nickenig serves as principal investigator, presenting 1-year EU data at CSI Frankfurt 2026 and DragonFly-FMR 12-month data at EuroPCR 2025. Bonn Heart Center is a key global KOL partner.
  • Xiamen University Affiliated Cardiovascular Hospital (厦心) - Prof. Wang Yan teamcoreImplementation/ SI/ Consulting PartnerKey clinical partner for "Belt and Road" international medical cooperation; treated an El Salvador medical expert with DragonFly™ in November 2025; conducts physician training and case demonstrations. Signed cooperation agreement with Rosales National Hospital in El Salvador (April 2025) and is a key node in Valgen's international clinical strategy.
  • ASV Yaşam Hospital, Antalya, Turkey - Prof. Ismail AteşcoreImplementation/ SI/ Consulting PartnerTurkish clinical partner presenting real-world evidence on 5 high-risk cases of complex mitral/tricuspid regurgitation at CSI Frankfurt 2026; serves as a key KOL reference for the Turkish and broader European market.
  • Fuwai Hospital, Chinese Academy of Medical Sciences - Prof. Pan Xiangbin team (中国医学科学院阜外医院)coreImplementation/ SI/ Consulting PartnerKey clinical partner in the development and clinical research of MitralStitch® — performed the first China-original DMR interventional case in 2018 and led the first-in-human clinical applications; supports "Belt and Road" medical cooperation programs.
  • Brazilian clinical center (local interventional cardiology hospital in São Paulo)minorImplementation/ SI/ Consulting PartnerBrazilian clinical center that performed the first Latin American commercial implant of DragonFly™ on April 30, 2026, validating device performance in complex AFMR cases.
  • Hanoi Medical University Hospital (Vietnam)minorImplementation/ SI/ Consulting PartnerPerformed the first Vietnam commercial implant of DragonFly™ on April 22, 2026 — a key clinical site for the Belt and Road Southeast Asia market entry.

Scale indicators17 records

Recent moves8 records

Expansion highlights6 records

Valgen Medtech competitors and assessment

Company assessment

Broad incumbents

  • MicroPort Scientific: Large Chinese medical device conglomerate with structural heart and other interventional portfolios. A broad incumbent with overlapping capabilities in structural heart and a wide distribution network across Chinese hospitals.
  • Edwards Lifesciences: Developer of the PASCAL transcatheter valve repair system, the second major global TEER platform competing directly with DragonFly™ and MitraClip. Edwards is a broad structural heart incumbent with established reimbursement and KOL penetration in EU and US markets.
  • Abbott: Global market leader in transcatheter mitral repair via the MitraClip system (now multi-generation G4). Directly competes with Valgen's DragonFly™ in both China and international markets, with the deepest global KOL network, longest follow-up data, and broadest reimbursement footprint.

Direct peers

  • Peijia Medical: Chinese structural heart company with a mitral and tricuspid valve interventional device portfolio. A direct domestic competitor to Valgen in the Chinese TEER and broader structural heart space, also pursuing international regulatory approvals.
  • Venus Medtech (Qiming Medical): Chinese structural heart company developing VenusP-Valve and other transcatheter valve products. Both a strategic investor in Valgen (participated in Series B) and exclusive domestic channel partner (Qiming Medical) for DragonFly™, as well as a peer in the broader Chinese structural heart interventional space.
  • Jenscare Scientific: Chinese medical device company developing the JensClip transcatheter mitral valve repair system, a direct domestic competitor to Valgen's DragonFly™ in the China TEER market. Competes for the same hospital accounts, surgeon training programs, and provincial reimbursement slots.

Emerging players

  • InnovHeart: Italy-based developer of the Saturn transcatheter mitral valve replacement system. An emerging player in the mitral regurgitation interventional space, focused on TMVR rather than TEER, addressing a related but distinct patient segment.
  • Cardiac Dimensions: Developer of the Carillon Mitral Contour System for functional mitral regurgitation. An emerging transcatheter alternative in the FMR space, addressing a subset of the same patient population that DragonFly™ is approved for (DragonFly received EU FMR approval in May 2026).
  • 4C Medical Technologies: US-based company developing the AltaValve transcatheter mitral valve replacement system. A partial competitor in the mitral regurgitation treatment space; overlaps in target patient population (high-risk MR) but with a different mechanism (TMVR vs TEER).

Regional players

  • NewMed Medical: Chinese structural heart company developing transcatheter valve products. A regional peer competing in the Chinese structural heart interventional market with overlapping target indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Valgen Medtech social profiles

Digital presence

Valgen Medtech compliance and trust

Trust signal

Compliance10 records

Valgen Medtech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valgen Medtech leadership team

Management profile

Number of profiles

Profiles2 records

Valgen Medtech funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valgen Medtech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valgen Medtech

What does Valgen Medtech do?

Valgen Medtech develops, manufactures, and commercializes Class III transcatheter interventional medical devices for structural heart disease, primarily mitral and tricuspid valve regurgitation. Its flagship DragonFly™ transcatheter mitral valve clip system performs transfemoral-transseptal edge-to-edge repair (TEER) and is sold alongside a procedural toolkit of supporting devices (MitralStitch®, DragonFly-T®, DragonFire®, DragonPath™, Magpie™, Pu Jie Jie™, stiff guidewires, and an adjustable curved introducer sheath) used by interventional cardiologists in hospitals.

Is Valgen Medtech a public or private company?

Valgen Medtech is a private company. It is classified as corporate owned and is currently operating.

When was Valgen Medtech founded?

Valgen Medtech was founded in 2015. It employs 11 to 50 people.

Where is Valgen Medtech based?

Valgen Medtech is headquartered in Hangzhou, China, in the Asia region.

How does Valgen Medtech make money?

Two revenue lines are on record. Medical device sales (capital equipment & consumables) is the primary driver. The others are international device sales & overseas commercialization.

Who are Valgen Medtech's main competitors?

Broad incumbents on record are MicroPort Scientific, Edwards Lifesciences and Abbott. Direct peers are Peijia Medical, Venus Medtech (Qiming Medical) and Jenscare Scientific. Emerging players are InnovHeart, Cardiac Dimensions and 4C Medical Technologies. NewMed Medical is listed as a regional player.

Does Valgen Medtech have an API?

No public API is recorded for Valgen Medtech.

What industry is Valgen Medtech in?

Valgen Medtech's product category is Interventional Cardiology Devices — Structural Heart (Transcatheter Mitral and Tricuspid Valve Repair). Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 339112 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDas DragonFly™-System von Valgen Medtech erhält EU-Zulassung für die Indikation FMRValgen Medtech's DragonFly transcatheter mitral valve repair system received EU CE marking for functional mitral regurgitation (FMR). The system is now the first Chinese transcatheter system with EU approval for both degenerative and functional mitral regurgitation. Clinical trial data showed 86.7% primary efficacy and 97.4% procedural success.PR NewswireLe système DragonFly™ de Valgen Medtech obtient l'autorisation de mise sur le marché de l'UE pour l'indication FMRValgen Medtech announced that its DragonFly™ transcatheter mitral valve repair system received CE marking from the European Union for the treatment of functional mitral regurgitation (FMR), making it the first Chinese-origin transcatheter mitral valve repair device authorized in the EU for both degenerative MR (DMR) and functional MR indications. The DragonFly-DMR European pivotal study demonstrated strong one-year outcomes, including 86.7% composite efficacy rate (freedom from all-cause mortality, mitral valve reintervention, and MR >2+) and 97.4% procedure success rate. The system has now obtained regulatory approvals in 15 countries and regions, with commercialization already underway in Latin America and Southeast Asia.PR NewswireValgen Medtech's DragonFly™ System Receives EU Approval for FMR IndicationValgen Medtech announced that its DragonFly™ Transcatheter Mitral Valve Repair System has received CE mark approval in the European Union for the treatment of Functional Mitral Regurgitation (FMR), making it the first transcatheter mitral valve repair device originating in China to receive EU approval for both DMR and FMR indications. One-year follow-up data from the DragonFly-DMR EU Pivotal Study showed 86.7% of patients achieved the composite primary effectiveness endpoint and 100% maintained MR severity at ≤2+, with both device implantation and procedural success rates reaching 97.4%. The DragonFly™ System has received regulatory approvals in 15 countries and regions, with commercial adoption underway in Latin America and Southeast Asia.PR NewswireNeues Transkatheter-Klappen-Reparatursystem: Ergebnisse der 12-monatigen Studie zu DRAGONFLY-DMR wurden auf der EuroPCR 2023 bekanntgegebenThe 12-month results of the DRAGONFLY-DMR pivotal clinical trial for the DragonFly trans-catheter mitral valve repair system were presented at EuroPCR 2023 on May 17, 2023, by Professor Scott Lim on behalf of lead investigator Professor Jian'an Wang from Zhe'er Hospital in Hangzhou, China. The trial met its primary efficacy endpoint, demonstrating a composite success rate of 87.5% at 12 months and an immediate procedural success rate of 99.2% among 120 enrolled patients across 27 medical centers in China. DragonFly was developed by Hangzhou Valgen Medtech Co., Ltd. and is expected to become China's first domestic transfemoral TEER product, with broader global availability anticipated.PR NewswireLos resultados del ensayo de 12 meses DRAGONFLY-DMR se presentan en EuroPCR 2023Valgen Medtech presented the 12-month results of the DRAGONFLY-DMR clinical trial at EuroPCR 2023, demonstrating that its DragonFly transcatheter valve device met its primary efficacy endpoint for treating degenerative mitral regurgitation. The study of 120 patients in China showed a composite success rate of 87.5% and significant improvements in patient quality of life and cardiac function. This data supports the safety and efficacy profile of the device, which is set to become the first nationally launched TEER product in China.PR NewswireChina marschiert vorwärts in das Zeitalter der interventionellen direkten AnuloplastieOn October 28, 2022, a multidisciplinary cardiac team at West China Hospital, Sichuan University, successfully performed the world's first human implantation of the "DragonRing" — a novel catheter-based transfemoral ring system for direct mitral valve annuloplasty developed by Hangzhou Valgen Medtech Co., Ltd. The device simulates surgical annuloplasty techniques in a minimally invasive approach and targets patients with functional mitral regurgitation, primarily caused by atrial fibrillation. International experts from the USA and Germany participated remotely via video conference, and Valgen Medtech indicated this marks another addition to its "Dragon" series pipeline of interventional structural heart products.PR NewswireChina marcha hacia la era de la anuloplastia directa intervencionistaHangzhou Valgen Medtech Co., Ltd. successfully performed the world's first human implantation of 'DragonRing,' an innovative transfemoral direct mitral annuloplasty device, on October 28, 2022. The procedure was led by Professor Mao Chen at West China Hospital in Sichuan, China, marking a significant advancement in minimally invasive treatment for functional mitral regurgitation. This event highlights Valgen Medtech's expansion of its 'Dragon-' series of interventional cardiac technologies.PR NewswireChina Marches into the Era of Interventional Direct AnnuloplastyOn October 28, 2022, a cardiac team led by Professor Mao Chen at West China Hospital, Sichuan University, successfully performed the world's first human implantation of the "DragonRing" interventional mitral annuloplasty device, developed by Hangzhou Valgen Medtech Co., Ltd. The procedure was conducted via transfemoral approach to treat functional mitral valve regurgitation in patients with atrial fibrillation as the primary etiology. International experts from the USA and Germany participated via remote video conferencing to observe and exchange techniques, and the subsequent study data is expected to further validate the device's clinical performance.PR NewswireChina Marches into the Era of Interventional Direct AnnuloplastyOn October 28, 2022, a cardiac team led by Professor Mao Chen at West China Hospital, Sichuan University, successfully performed the world's first human implantation of the "DragonRing" catheter-based mitral annuloplasty device, developed by Hangzhou Valgen Medtech Co., Ltd. of China. The device is designed to treat functional mitral valve regurgitation by cinching the dilated annulus in a minimally invasive manner, simulating surgical annuloplasty techniques. International cardiac experts from the USA and Germany participated via remote video conferencing to observe and discuss the procedure.